CN116209663A - 用于靶向pd-l1的方法和组合物 - Google Patents
用于靶向pd-l1的方法和组合物 Download PDFInfo
- Publication number
- CN116209663A CN116209663A CN202180062965.1A CN202180062965A CN116209663A CN 116209663 A CN116209663 A CN 116209663A CN 202180062965 A CN202180062965 A CN 202180062965A CN 116209663 A CN116209663 A CN 116209663A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- alkyl
- monocyclic
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066689P | 2020-08-17 | 2020-08-17 | |
| US63/066,689 | 2020-08-17 | ||
| US202163210423P | 2021-06-14 | 2021-06-14 | |
| US63/210,423 | 2021-06-14 | ||
| PCT/US2021/045696 WO2022040002A1 (en) | 2020-08-17 | 2021-08-12 | Methods and compositions for targeting pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116209663A true CN116209663A (zh) | 2023-06-02 |
Family
ID=80350607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180062965.1A Pending CN116209663A (zh) | 2020-08-17 | 2021-08-12 | 用于靶向pd-l1的方法和组合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11760761B2 (enExample) |
| EP (1) | EP4185569B1 (enExample) |
| JP (1) | JP2023539463A (enExample) |
| KR (1) | KR20230059801A (enExample) |
| CN (1) | CN116209663A (enExample) |
| AU (1) | AU2021329259A1 (enExample) |
| CA (1) | CA3190154A1 (enExample) |
| TW (1) | TW202227451A (enExample) |
| WO (1) | WO2022040002A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021275118A1 (en) | 2020-05-22 | 2022-12-01 | Aligos Therapeutics, Inc. | Methods and compositions for targeting PD-L1 |
| CN115232109A (zh) * | 2021-04-25 | 2022-10-25 | 广东东阳光药业有限公司 | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 |
| MX2023014754A (es) | 2021-06-18 | 2024-02-12 | Aligos Therapeutics Inc | Métodos y composiciones dirigidos a pd-l1. |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12065428B2 (en) | 2021-09-17 | 2024-08-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| CN119212987A (zh) | 2021-12-16 | 2024-12-27 | 安力高医药股份有限公司 | 用于靶向pd-l1的方法和组合物 |
| AU2023303408A1 (en) | 2022-07-06 | 2024-12-19 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2024134466A1 (en) * | 2022-12-21 | 2024-06-27 | Arbutus Biopharma Corporation | Substituted arylamine compounds, substituted heteroarylamine compounds, and methods using same |
| AU2024224371A1 (en) * | 2023-02-23 | 2025-08-07 | Sunshine Lake Pharma Co., Ltd. | Pyridopyrimidine derivative and use thereof |
| WO2025015063A1 (en) * | 2023-07-13 | 2025-01-16 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| WO2025171031A1 (en) * | 2024-02-07 | 2025-08-14 | Aligos Therapeutics, Inc. | Pd-l1 compounds with a bicyclic group |
| WO2025171025A1 (en) * | 2024-02-07 | 2025-08-14 | Aligos Therapeutics, Inc. | Pd-l1 compounds with a bicyclic group |
| WO2025174835A1 (en) * | 2024-02-15 | 2025-08-21 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| WO2025199281A1 (en) * | 2024-03-22 | 2025-09-25 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| WO2025199273A1 (en) * | 2024-03-22 | 2025-09-25 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE180771T1 (de) | 1989-07-17 | 1999-06-15 | Dow Chemical Co | Mesogene polycyanate und polycyanamide und ihre hitzegehärteten gegenstände |
| AU2002368274A1 (en) | 2001-09-13 | 2004-06-03 | Genesoft, Inc. | Methods of treating infection by drug resistant bacteria |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| FR2913883B1 (fr) | 2007-03-20 | 2009-06-05 | Oreal | Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose |
| KR20100033981A (ko) | 2007-06-03 | 2010-03-31 | 벤더르빌트 유니버시티 | 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법 |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
| US8049411B2 (en) | 2008-06-05 | 2011-11-01 | Idemitsu Kosan Co., Ltd. | Material for organic electroluminescence device and organic electroluminescence device using the same |
| CN102056911B (zh) | 2008-06-05 | 2015-07-22 | 出光兴产株式会社 | 卤素化合物、多环系化合物及使用其的有机电致发光元件 |
| JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
| AU2010333338A1 (en) | 2009-12-14 | 2012-08-02 | Merck Patent Gmbh | Sphingosine kinase inhibitors |
| PL2526093T3 (pl) | 2010-01-22 | 2017-02-28 | Acetylon Pharmaceuticals, Inc. | Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania |
| JP2012051874A (ja) | 2010-07-28 | 2012-03-15 | Sumitomo Chemical Co Ltd | 縮合環化合物、有機薄膜及び有機薄膜素子 |
| JP2012126876A (ja) | 2010-11-24 | 2012-07-05 | Sumitomo Chemical Co Ltd | 共役系化合物、並びにこれを用いた有機薄膜及び有機薄膜素子 |
| KR101848885B1 (ko) | 2012-10-29 | 2018-04-16 | 삼성디스플레이 주식회사 | 아민계 화합물 및 이를 포함한 유기 발광 소자 |
| KR102121582B1 (ko) | 2012-12-12 | 2020-06-10 | 에스에프씨 주식회사 | 피렌계 화합물 및 이를 이용한 유기전계발광소자 |
| US9458125B2 (en) | 2012-12-17 | 2016-10-04 | Jnc Corporation | Octahydro binaphthyl-based chiral compound-containing liquid-crystal composition and optical element |
| KR102086547B1 (ko) | 2013-02-13 | 2020-05-28 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR20140140417A (ko) | 2013-05-29 | 2014-12-09 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102098738B1 (ko) | 2013-07-09 | 2020-06-01 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US9871205B2 (en) | 2013-08-02 | 2018-01-16 | Samsung Display Co., Ltd. | Organic light-emitting device |
| KR102086556B1 (ko) | 2013-08-02 | 2020-03-10 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR20150035317A (ko) | 2013-09-27 | 2015-04-06 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| WO2015063046A1 (en) | 2013-10-31 | 2015-05-07 | Basf Se | Azadibenzothiophenes for electronic applications |
| US10158083B2 (en) | 2013-12-12 | 2018-12-18 | Merck Patent Gmbh | Materials for electronic devices |
| KR101670056B1 (ko) | 2014-02-20 | 2016-10-28 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR101806164B1 (ko) | 2014-03-24 | 2017-12-07 | 주식회사 스킨앤스킨 | 신규한 유기발광화합물 및 이를 포함하는 유기 발광 소자 |
| KR101735688B1 (ko) | 2014-06-17 | 2017-05-15 | 주식회사 엘지화학 | 고리형 올레핀 화합물, 광반응성 중합체 및 이를 포함하는 배향막 |
| CN106065009B (zh) | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| KR101641023B1 (ko) | 2014-08-27 | 2016-07-20 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
| WO2016032120A1 (ko) | 2014-08-27 | 2016-03-03 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
| CN107075375B (zh) | 2014-12-25 | 2020-11-13 | Dic株式会社 | 向列液晶组合物及使用其的液晶显示元件 |
| KR102384224B1 (ko) | 2014-12-30 | 2022-04-08 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| KR101910112B1 (ko) | 2015-05-06 | 2018-10-19 | 삼성에스디아이 주식회사 | 유기광전자소자용 도펀트, 유기광전자소자 및 표시장치 |
| EP3294695B1 (en) * | 2015-05-11 | 2020-09-30 | Compact Membrane Systems, Inc. | Thin film composite membranes for separation of alkenes from alkanes |
| KR102002034B1 (ko) | 2015-07-09 | 2019-07-22 | 에스에프씨주식회사 | 고효율과 장수명을 갖는 유기 발광 소자 |
| US10690952B2 (en) | 2015-08-11 | 2020-06-23 | Dic Corporation | Liquid crystal display element |
| JP6808916B2 (ja) | 2015-08-11 | 2021-01-06 | Dic株式会社 | 液晶表示素子 |
| CN107850810B (zh) | 2015-08-11 | 2021-06-15 | Dic株式会社 | 液晶显示元件 |
| JP6949055B2 (ja) | 2016-02-05 | 2021-10-13 | ヴェラ ファーマシューティカルズ，エルエルシー | 感染症を治療するための組成物および方法 |
| KR102111149B1 (ko) | 2016-11-11 | 2020-05-14 | 주식회사 엘지화학 | 유기 발광 소자 |
| KR102044806B1 (ko) | 2017-02-15 | 2019-11-15 | 기초과학연구원 | 신규한 화합물 및 이의 용도 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN109265471B (zh) | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| KR102377225B1 (ko) | 2017-07-13 | 2022-03-22 | 에스에프씨주식회사 | 고효율 및 장수명 특성을 가지는 유기 발광 소자 |
| JP6801796B2 (ja) | 2017-12-22 | 2020-12-16 | Dic株式会社 | 重合性液晶組成物及び液晶表示素子ならびに重合性化合物 |
| WO2019127008A1 (zh) | 2017-12-26 | 2019-07-04 | 清华大学 | 一种靶向降解btk的化合物及其应用 |
| WO2019160882A1 (en) * | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102679423B1 (ko) | 2018-03-13 | 2024-07-02 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| CN116332914B (zh) | 2018-03-29 | 2025-04-15 | 德山新勒克斯有限公司 | 用于有机电气元件的化合物、使用所述化合物的有机电气元件及其电子装置 |
| KR102591947B1 (ko) * | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019212290A1 (ko) | 2018-05-04 | 2019-11-07 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| KR102617841B1 (ko) | 2018-05-29 | 2023-12-26 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| CN110372693B (zh) | 2018-07-04 | 2022-05-03 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
| WO2020006724A1 (zh) | 2018-07-05 | 2020-01-09 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
| CN108794453A (zh) | 2018-07-05 | 2018-11-13 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
| PE20210642A1 (es) * | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| AU2019364417A1 (en) | 2018-10-24 | 2021-05-20 | Araxes Pharma Llc | 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis |
| CN111423422A (zh) | 2019-01-09 | 2020-07-17 | 苏州泽璟生物制药股份有限公司 | 芳基酰胺类抑制剂及其制备方法和应用 |
| EP4100381A4 (en) | 2020-02-03 | 2024-04-03 | Arbutus Biopharma Corporation | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS OF USE THEREOF |
| AU2021275118A1 (en) | 2020-05-22 | 2022-12-01 | Aligos Therapeutics, Inc. | Methods and compositions for targeting PD-L1 |
| MX2023014754A (es) | 2021-06-18 | 2024-02-12 | Aligos Therapeutics Inc | Métodos y composiciones dirigidos a pd-l1. |
-
2021
- 2021-08-12 KR KR1020237008638A patent/KR20230059801A/ko not_active Ceased
- 2021-08-12 WO PCT/US2021/045696 patent/WO2022040002A1/en not_active Ceased
- 2021-08-12 CA CA3190154A patent/CA3190154A1/en active Pending
- 2021-08-12 EP EP21858851.5A patent/EP4185569B1/en active Active
- 2021-08-12 CN CN202180062965.1A patent/CN116209663A/zh active Pending
- 2021-08-12 US US17/444,947 patent/US11760761B2/en active Active
- 2021-08-12 AU AU2021329259A patent/AU2021329259A1/en active Pending
- 2021-08-12 JP JP2023512031A patent/JP2023539463A/ja active Pending
- 2021-08-16 TW TW110130151A patent/TW202227451A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021329259A1 (en) | 2023-03-02 |
| JP2023539463A (ja) | 2023-09-14 |
| WO2022040002A1 (en) | 2022-02-24 |
| EP4185569A4 (en) | 2024-09-04 |
| EP4185569B1 (en) | 2026-02-25 |
| US20230065527A1 (en) | 2023-03-02 |
| EP4185569C0 (en) | 2026-02-25 |
| US11760761B2 (en) | 2023-09-19 |
| CA3190154A1 (en) | 2022-02-24 |
| EP4185569A1 (en) | 2023-05-31 |
| TW202227451A (zh) | 2022-07-16 |
| KR20230059801A (ko) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4185569B1 (en) | Methods and compositions for targeting pd-l1 | |
| TWI893530B (zh) | Pd‐1/pd‐l1抑制劑 | |
| US12018015B2 (en) | Methods and compositions for targeting PD-L1 | |
| EP3294732B1 (en) | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase | |
| CN119212987A (zh) | 用于靶向pd-l1的方法和组合物 | |
| TW202208320A (zh) | 靶向pd-l1之方法及組合物 | |
| TWI858267B (zh) | 用於治療hiv之蛋白殼抑制劑 | |
| EP4626879A1 (en) | Methods and compositions for targeting pd-l1 | |
| WO2025015063A1 (en) | Methods and compositions for targeting pd-l1 | |
| HK40111515A (en) | Methods and compositions for targeting pd-l1 | |
| CN117813090A (zh) | 用于靶向pd-l1的方法和组合物 | |
| WO2025171031A1 (en) | Pd-l1 compounds with a bicyclic group | |
| WO2025199273A1 (en) | Methods and compositions for targeting pd-l1 | |
| WO2025199281A1 (en) | Methods and compositions for targeting pd-l1 | |
| HK40076587A (en) | Pd-1/pd-l1 inhibitors | |
| HK40022913A (en) | Pd-1/pd-l1 inhibitors | |
| HK1244796B (en) | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |